Insider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells $197,316.00 in Stock

by · The Markets Daily

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) insider Lai Wang sold 756 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $261.00, for a total value of $197,316.00. Following the completion of the sale, the insider owned 1,710,085 shares in the company, valued at $446,332,185. This represents a 0.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lai Wang also recently made the following trade(s):

  • On Monday, June 8th, Lai Wang sold 1,367 shares of BeOne Medicines stock. The shares were sold at an average price of $269.38, for a total value of $368,242.46.

BeOne Medicines Stock Down 0.5%

ONC stock opened at $262.68 on Thursday. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $28.82 billion, a PE ratio of 58.77 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22. The business’s 50 day simple moving average is $296.83 and its 200 day simple moving average is $312.94.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion during the quarter. As a group, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds have recently bought and sold shares of the business. EFG International AG bought a new stake in BeOne Medicines in the 4th quarter valued at about $25,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines in the second quarter valued at approximately $35,000. CWM LLC grew its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares in the last quarter. Finally, Group One Trading LLC acquired a new stake in BeOne Medicines during the fourth quarter worth approximately $61,000. 48.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on ONC shares. Leerink Partners lifted their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Barclays increased their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Truist Financial reaffirmed a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Finally, Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

Check Out Our Latest Report on ONC

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Read More